JW SHINYAK CORPORATION
Financials
Valuation Metrics
JW SHINYAK CORPORATION's Market Cap is ₩1897B. At end of 2025 it was ₩1194B. Ranked #882 of 2,421 in KR market (top 36%), #417 of 1,640 on KOSDAQ (top 25%), #94 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 189.69B KRW | KR#882/2,421 Sec#94/231 |
| Revenue | 84.61B KRW | KR#1,518/2,421 Sec#95/231 |
| Net Income | 10.22B KRW | KR#965/2,421 Sec#61/231 |
| Total Assets | 61.91B KRW | KR#2,086/2,421 Sec#181/231 |
| Net Assets | 40.74B KRW | KR#2,035/2,421 Sec#178/231 |
| Employees | 188 | KR#1,145/2,421 Sec#94/231 |
| Value | ||
| P/E | 18.56x | KR#1,138/2,421 Sec#69/231 |
| P/B | 4.66x | KR#2,227/2,421 Sec#188/231 |
| P/S | 2.24x | KR#1,874/2,421 Sec#108/231 |
| EV/EBITDA | 18.35x | KR#961/2,421 Sec#55/231 |
| FCF Yield | 2.34% | KR#1,032/2,421 Sec#67/231 |
| Profitability | ||
| ROE | 25.09% | KR#100/2,421 Sec#7/231 |
| ROA | 16.51% | KR#87/2,421 Sec#8/231 |
| Op. Margin | 12.51% | KR#391/2,421 Sec#34/231 |
| Revenue Growth | -2.68% | KR#1,664/2,421 Sec#161/231 |
| Earnings Growth | -27.51% | KR#968/2,421 Sec#62/231 |
| Financial Health | ||
| Debt Ratio | 51.98% | KR#985/2,421 Sec#116/231 |
| Total Debt | 4.70B KRW | KR#1,805/2,421 Sec#173/231 |
| FCF | 4.44B KRW | KR#938/2,421 Sec#65/231 |
| Cash | 128.6M KRW | KR#2,383/2,421 Sec#228/231 |
| Current Ratio | 1.55x | KR#1,156/2,421 Sec#126/231 |
| Net Debt/EBITDA | 0.43x | KR#659/2,421 Sec#39/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 135.72% | KR#91/2,421 Sec#5/231 |
| 1M Return | 57.44% | KR#41/2,421 Sec#7/231 |
| From 52W High | -21.91% | KR#295/2,421 Sec#13/231 |
| 1Y MDD | -55.68% | KR#1,243/2,421 Sec#101/231 |
| Trading | ||
| Volume | 4,726,263 shares | KR#30/2,421 Sec#2/231 |
| Trading Value | 16.31B KRW | KR#190/2,421 Sec#13/231 |
| Foreign Own. | 1.54% | KR#1,816/2,421 Sec#178/231 |
| Per Share | ||
| EPS | 182 KRW | KR#1,312/2,421 Sec#86/231 |
| BPS | 727 KRW | KR#2,355/2,421 Sec#220/231 |
Company Info
Established in 1975, the company was listed on KOSDAQ in 2003 and rebranded as JW Shin Yak in 2016 after absorbing the former Joongwae Shin Yak in 2009. It manufactures and sells specialized pharmaceuticals, including antifungals and urological agents, serving the dermatology, urology, pediatrics, and internal medicine markets. JW Shin Yak is developing CAR-NK therapies using macrophage gene manipulation technology to enter the next-generation anti-cancer market and expand into the hair loss and cosmeceutical sectors. The company is headquartered in Gwacheon, Gyeonggi Province.